Related Experiment Video
Updated: May 5, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Use of relative effectiveness information in reimbursement and pricing decisions in Europe
Floortje van Nooten1, J Jaime Caro
1United BioSource Corporation, 26-28 Hammersmith Grove, London, W6 7HA, UK.
Abstract:
Although comparative effectiveness has received considerable attention recently - especially in the USA - it is not a new concept. In Europe, it has been applied for some time now in the pricing and reimbursement processes of many countries. Each one uses it in its own way, however, with variations in the precise definition and the role it plays in the process. It remains to be seen whether the implementation of comparative effectiveness becomes more harmonized and whether it will be integrated better with the registration process. Regardless of the extent to which it is standardized, obtaining the data will remain a substantial hurdle, both methodologically and operationally. Everyone wants comparative effectiveness information but no one knows quite how to make it happen.
More Related Videos
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Related Concept Videos
Relative Risk
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Bioequivalence: Overview
Bioequivalence Data: Statistical Interpretation
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Bioavailability Study Design: Absolute Versus Relative Bioavailability